|Bid||8.43 x 1000|
|Ask||8.59 x 1000|
|Day's Range||8.43 - 8.46|
|52 Week Range||7.24 - 9.46|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||22.25|
|Earnings Date||Aug 12, 2019 - Aug 22, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.75|
Stamford, Connecticut , May 23, 2019 (GLOBE NEWSWIRE) -- Rubicon Technology, Inc. (RBCN) announced today it has acquired certain equipment and assets from a large Indiana based pharmacy operation, including its licenses to operate in 11 states. Rubicon DTP LLC, a newly formed wholly owned subsidiary of Rubicon Technology, will primarily operate this business under the name Direct Dose Rx. Direct Dose Rx is focused on the delivery of prescription medication, over-the-counter drugs and vitamins to skilled nursing facilities and hospitals for patients that are being discharged.
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Rubicon Technology, Inc. (RBCN) today announced that its Board of Directors has authorized a stock repurchase plan to buy up to $3 million of its common stock from time to time through open market and private transactions. The timing, price and volume of repurchases will be based upon market conditions, relevant securities laws and other factors. The stock repurchase plan expires on November 19, 2021 and may be terminated at any time. “In our opinion, shares of Rubicon’s common stock are currently trading at a discount to its intrinsic value.